Novartis settles Gleevec patent litigation

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis (NVS +0.6%) settles its patent fight with the U.S. subsidiary of Sun Pharmaceutical Industries over a generic form of Gleevec (imatinib mesylate). Under the terms of the settlement Sun can launch a generic version on February 1, 2016.

Novartis' patents cover certain polymorphic forms of imatinib mesylate which expire in 2019, including pediatric exclusivity, but its compound patent expires in the U.S. on July 4, 2015.

No other terms are disclosed.